Laboratorios Farmaceuticos Rovi SA 2015 AR2
The report highlights Laboratorios Farmaceuticos Rovi's financial and non-financial performance for the fiscal year 2015. The company achieved record total revenues of 247.0 million euros, representing a 3% increase compared to the previous year, driven by its contract manufacturing and pharmaceutical specialties businesses. Key milestones included the acquisition of a new injectable plant in San Sebastian de los Reyes and the successful completion of the Risperidone ISM PRISMA-2 clinical trial. In terms of sustainability, the company reduced its total waste generation by 17% and continued its commitment to equal opportunities, with women representing over half of its average workforce of 1,102 employees.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2015
Type: AR2
Pages: 116
Back to company
Laboratorios Farmaceuticos Rovi SA
Annual Report
The report highlights Laboratorios Farmaceuticos Rovi's financial and non-financial performance for the fiscal year 2015. The company achieved record total revenues of 247.0 million euros, representing a 3% increase compared to the previous year, driven by its contract manufacturing and pharmaceutical specialties businesses. Key milestones included the acquisition of a new injectable plant in San Sebastian de los Reyes and the successful completion of the Risperidone ISM PRISMA-2 clinical trial. In terms of sustainability, the company reduced its total waste generation by 17% and continued its commitment to equal opportunities, with women representing over half of its average workforce of 1,102 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Employees